Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: Is prostate cancer detection compromised in patients receiving long- term dialysis?

Urology

Volumn 53, Issue 6, 1999, Pages 1169-1174

  Djavan, Bob ^a   Shariat, Shahrokh ^a   Ghawidel, Keywan ^a   G̈uven Marberger, Kathrin ^a   Remzi, Mesut ^a   Kovarik, Josef ^a   Hoerl, Walter H ^a   Marberger, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GLOMERULUS FILTRATION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; ULTRAFILTRATION; UREA NITROGEN BLOOD LEVEL;

EID: 0033151968     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00010-2     Document Type: Article

References (26)

1. Matas A.J., Simmons R.L., Kjellstrand C.M., et al. Increased incidence of malignancy during chronic renal failure. Lancet. i:1975;883-888.
2. Lindner A., Farewell V.T., Sherrad D.J. High incidence of neoplasia in uremic patients receiving long term dialysis. Nephron. 27:1981;292-296.
3. Slifkin R.F., Goldberg J., Neff M.S., et al. Malignancy in end-stage renal disease. Trans Am Soc Artif Intern Organ. 32:1977;43-48.
4. Port F.K., Ragheb N.E., Schwartz A.G., et al. Neoplasms in dialysis patients a population based study . Am J Kidney Dis. 14:1989;119-123.
5. Makita Y., Iwamoto T., Sagiyama K., et al. Two cases of urogenital malignancies in male patients undergoing maintenance hemodialysis. Int Urol Nephrol. 26:1994;713-718.
6. Marple J.T., MacDougall M. Development of malignancy in the end-stage renal disease patients. Semin Nephrol. 13:1993;306-314.
7. Parker S.L., Tong T., Bolden S., et al. Cancer statistics 1997. CA Cancer J Clin. 47:1997;5-27.
8. Brawer M.K. Prostate specific antigen critical issues . Urology. 44:(6A):1994;9-17.
9. Djavan B., Zlotta A.R., Byttebier G., et al. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol. 160:1998;411-419.
10. Watt K.W., Lee P.J., M'Timkulu T., et al. Human prostate specific antigen structural and functional similarity with serine proteases . Proc Natl Acad Sci USA. 83:1986;A3166-A3170.
11. Christensson A., Laurell C.B., Lilja H. Enzymatic activity of prostate specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 194:1990;755-763.
12. Lilja H., Christensson A., Dahlen U., et al. Prostate specific antigen in serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem. 37:1991;1618-1625.
13. Catalona W.J., Smith D.S., Wolfert R.L., et al. Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA. 274:1995;1214-1220.
14. Vashi A.R., Wojno K.J., Henricks W., et al. Determination of the reflex range and appropriate cut points for percent free prostate specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology. 49:1997;19-27.
15. Harper L., McIntyre C.W., MacDougall I.C., et al. Prostate specific antigen levels in patients receiving long term dialysis. Br J Urol. 76:1995;482-483.
16. Sasagawa I., Kubota Y., Hayami S., et al. Serum level of total and free prostate specific antigen in men on hemodialysis. J Urol. 160:1998;83-85.
17. Morton J.J., Howe S.F., Lowell J.A., et al. Influence of end stage renal disease and renal transplantation on serum prostate specific antigen. Br J Urol. 75:1995;498-501.
18. Sasagawa I., Nakada T., Hashimoto T., et al. Serum prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in hemodialysis patients. Urol Int. 48:1992;181-183.
19. Monath J.R., Burkat J.M., Freedman B.I., et al. Effects of hemodialysis on prostatic specific antigen. Urology. 42:1993;398-400.
20. Kabalin J.N., Hornberger J.C. Prostatic specific antigen is not excreted by human kidney or eliminated by routine hemodialysis. Urology. 37:1991;308-310.
21. Agha A.H., Schechter E., Roy J.B., et al. Prostatic specific antigen is metabolized in the liver. J Urol. 155:1996;1332-1335.
22. Bjork T., Ljungberg B., Piironen T., et al. Rapid exponential elimination of the free prostate specific antigen contrasts with the slow, space capacity elimination PSA complexed to alpha-1-antichymotrypsin from serum. Urology. 51:1998;57-62.
23. Lye W.C., Tambyah P., Leong S.O., et al. Serum tumor markers in patients on dialysis and kidney transplantation. Adv Perit Dial. 10:1994;109-111.
24. Rockel A., Gilge U., Liewald A., et al. Elimination of low molecular weight proteins during hemofiltration. Int Soc Artif Organs. 6:1982;307-315.
25. Parzer S., Balcke P. Plasma protein adsorption to hemodialysis membranes. J Biomed Mater Res. 27:1993;455-463.
26. Pascual M., Tolkoff-Rubin N., Schifferli J.A. Is adsorption an important characteristic of dialysis membranes? Kidney Int. 49:1996;309-313.